8-K: Amphastar Q3 Net Income Plunges on Litigation Charge

Amphastar Pharmaceuticals reported Q3 2025 net revenues of $191.8 million, flat year-over-year, with GAAP net income significantly impacted by a $23.1 million litigation provision.

Summary

• Net revenues for the three months ended September 30, 2025, were $191.8 million, a marginal increase from $191.2 million in the same period last year.
• GAAP net income for Q3 2025 decreased significantly to $17.4 million ($0.37 per diluted share) from $40.4 million ($0.78 per diluted share) in Q3 2024.
• Adjusted non-GAAP net income for Q3 2025 was $44.7 million ($0.93 per diluted share), down from $49.6 million ($0.96 per diluted share) in Q3 2024.
• BAQSIMI product sales increased 33% to $53.6 million, driven by increased unit volumes and expanded marketing efforts; total BAQSIMI sales, including prior quarter sales by Eli Lilly and Company, grew 14% from the prior year's quarter.
• Primatene MIST sales increased 11% to $28.8 million due to higher unit volumes.
• Epinephrine sales decreased 12% due to a lower average selling price of the multi-dose vial product from increased competition, partially offset by increased unit volumes for the pre-filled syringe due to supplier shortages.
• Glucagon sales declined 49% due to a lower average selling price and decreased unit volumes, resulting from competition and a shift to ready-to-use glucagon products.
• Lidocaine sales decreased 19% due to other suppliers returning to their historical distribution levels.
• The company launched iron sucrose injection in August 2025, contributing $2.4 million in sales.
• An exclusive licensing agreement was entered into with Nanjing Anji Biotechnology for three novel peptides targeting high-growth oncology and ophthalmology markets.
• Cash flow provided by operating activities for the nine months ended September 30, 2025, was $123.3 million.

Sentiment

Score: 4

Explanation: The significant drop in GAAP net income and EPS due to a large litigation provision, coupled with declines in several established product lines due to competition, indicates a challenging quarter. While BAQSIMI and Primatene MIST showed strong growth and pipeline expansion is positive, the overall financial performance, particularly on a GAAP basis, is concerning.

Positives

• BAQSIMI product sales increased 33% to $53.6 million in Q3 2025, driven by expanded marketing and unit volume growth.
• Primatene MIST sales grew 11% to $28.8 million in Q3 2025 due to increased unit volumes and continued marketing efforts.
• Successfully launched iron sucrose injection in August 2025, contributing $2.4 million in sales and expanding patient access to affordable therapies.
• Bolstered proprietary pipeline through an exclusive licensing agreement for three novel peptides targeting high-growth oncology and ophthalmology markets.
• Cash and cash equivalents increased to $216.3 million as of September 30, 2025, from $151.6 million at December 31, 2024.
• The company's pipeline includes 3 abbreviated new drug applications (ANDAs), 1 biosimilar insulin candidate (targeting products with a combined market size exceeding $2 billion), 3 biosimilar products in development (targeting products with a market size exceeding $6 billion), and 2 generic products in development (targeting products with a market size of over $1 billion).

Negatives

• GAAP net income for Q3 2025 decreased 57% to $17.4 million from $40.4 million in Q3 2024.
• GAAP diluted EPS decreased 53% to $0.37 in Q3 2025 from $0.78 in Q3 2024.
• General and administrative expenses increased 166% primarily due to a $23.1 million litigation provision.
• Gross profit decreased 3% to $98.6 million, and gross margin declined to 51.4% from 53.3% in Q3 2024.
• Glucagon sales decreased 49% due to lower average selling price and decreased unit volumes from competition and market shifts.
• Epinephrine sales decreased 12% due to lower average selling prices from increased competition.
• Lidocaine sales decreased 19% due to other suppliers returning to historical distribution levels.

Risks

• Increased competition leading to lower average selling prices for products such as epinephrine multi-dose vial and glucagon.
• Competition and the continued shift to ready-to-use products (e.g., glucagon) impacting sales volumes and pricing.
• There is no guarantee that sales strategies will be successful, or that the company will continue to experience significant sales of BAQSIMI.
• General risks, uncertainties, and assumptions inherent in forward-looking statements, as detailed in the company's other SEC filings, which are difficult or impossible to predict and, in some cases, beyond the company's control.

Future Outlook

The company is positioned to accelerate growth and drive long-term value across its portfolio through sustained commercial momentum, strategic pipeline expansion, and recent FDA approvals. The pipeline includes three ANDAs, one biosimilar insulin candidate, three biosimilar products, and two generic products in development, targeting combined market sizes exceeding $9 billion based on IQVIA data for the 12 months ended September 30, 2025. The exclusive licensing agreement for three novel peptides is expected to bolster the proprietary pipeline in high-growth oncology and ophthalmology markets.

Management Comments

• "Amphastar delivered another strong quarter, led by double-digit growth from BAQSIMI, which achieved a 14% increase in revenue compared to the same period last year." Dr. Jack Zhang, President and Chief Executive Officer.
• "Additionally, we received FDA approval and launched iron sucrose injection, a key generic alternative which expands patient access to affordable therapies while contributing to our revenue growth." Dr. Jack Zhang, President and Chief Executive Officer.
• "This achievement underscores our commitment to advancing complex generics and leveraging our domestic in-house manufacturing expertise to deliver high-quality therapies to patients." Dr. Jack Zhang, President and Chief Executive Officer.
• "In addition, we bolstered our proprietary pipeline through an exclusive licensing agreement with Nanjing Anji Biotechnology to develop and commercialize three novel peptides targeting high-growth markets across oncology and ophthalmology." Dr. Jack Zhang, President and Chief Executive Officer.
• "Together, our sustained commercial momentum, strategic pipeline expansion, and recent FDA approval, position Amphastar to accelerate growth and drive long-term value across its portfolio." Dr. Jack Zhang, President and Chief Executive Officer.

Industry Context

Amphastar operates in the highly competitive biopharmaceutical industry, particularly in complex generics and proprietary injectables. The decline in sales for products like Epinephrine, Glucagon, and Lidocaine due to increased competition and pricing pressure reflects a broader trend in the generic drug market where new entrants can quickly erode market share and margins. The strategic focus on expanding the proprietary pipeline through licensing agreements and developing biosimilars and novel peptides aligns with industry efforts to diversify revenue streams and move towards higher-margin specialty products, mitigating the impact of generic erosion.

Legal Proceedings

• A litigation provision of $23.1 million was recorded, significantly increasing General and Administrative expenses for the quarter.

Stakeholder Impact

• Shareholders: Significant decrease in GAAP net income and EPS could negatively impact investor sentiment and share price. However, strong growth in key products and pipeline expansion offer long-term potential.
• Customers: The launch of iron sucrose injection expands access to affordable therapies. Increased competition for some products may lead to lower prices for customers.
• Employees: Continued marketing efforts and pipeline expansion suggest ongoing operational activity and potential for future growth.
• Competitors: Increased competition is noted as impacting sales and pricing for several of Amphastar's products, indicating a dynamic market environment.

Next Steps

• Continue sales and marketing efforts for BAQSIMI and Primatene MIST.
• Advance the development, manufacturing, use, and commercialization of three novel peptides from the Nanjing Anji Biotechnology licensing agreement.
• Progress the pipeline of three ANDAs, one biosimilar insulin candidate, three biosimilar products, and two generic products in development.
• Hold a conference call on November 6, 2025, at 2:00 p.m. Pacific Time to discuss financial results.

Key Dates

Recommendation

While Amphastar demonstrated strong growth in key products like BAQSIMI and strategically expanded its pipeline with a new licensing agreement and product launch, the significant decline in GAAP net income and EPS due to a large litigation provision is a major concern. The erosion of sales in other established products due to competition and pricing pressure also highlights underlying market challenges. The non-GAAP results show a more stable operational picture, but the GAAP impact cannot be ignored. Investors should hold to monitor the resolution of the litigation, the performance of new products, and the progress of the expanded pipeline to assess if these strategic initiatives can offset competitive pressures and one-time charges in the long term.

Keywords

Amphastar Pharmaceuticals, AMPH, Q3 2025 Earnings, Financial Results, Biopharmaceutical, Generic Drugs, Injectable Products, Inhalation Products, Intranasal Products, BAQSIMI, Primatene MIST, Epinephrine, Glucagon, Lidocaine, Iron Sucrose Injection, Pipeline, Oncology, Ophthalmology, FDA Approval, Licensing Agreement, Litigation Provision